Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Launched by BOSTON SCIENTIFIC CORPORATION · Feb 10, 2025
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a treatment called the Intracept™ Intraosseous Nerve Ablation System for people suffering from chronic low back pain, specifically pain caused by vertebrogenic conditions. The goal is to gather real-world information about how well this treatment works for patients who are already scheduled to receive it.
If you are between the ages of 65 and 74 and have been diagnosed with vertebrogenic pain, you may be eligible to participate in this trial. To join, you will need to give your consent after learning about the study, and you must not have any health issues that would prevent you from using the treatment according to the guidelines. Participants can expect to share their experiences with the treatment, which could help improve care for others with similar pain. The trial is currently in the recruiting phase, meaning they are looking for volunteers to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
- • Signed a valid, IRB/EC-approved informed consent form.
- Exclusion Criteria:
- • Meets any contraindications per locally applicable Instructions for Use (IFU).
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Salt Lake City, Utah, United States
New Orleans, Louisiana, United States
Westport, Connecticut, United States
Eugene, Oregon, United States
Larkspur, California, United States
Post Falls, Idaho, United States
Maple Grove, Minnesota, United States
Patients applied
Trial Officials
Natalie Bloom Lyons, M.A.
Study Director
Boston Scientific Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported